Factors related to upstaging of clinical stage T2 organ-confined bladder cancer following radical cystectomy: A multicenter study

Mahmoud Shoukry El-Adawy, Hisham Ibrahim¹, Fouad Zanaty², Sameh Kotb¹
Department of Urology, Fayoum University, Fayoum, ¹Department of Urology, Cairo University, Cairo, ²Department of Urology, Menoufia University, Menoufia, Egypt

Abstract

Aims: This study aimed to detect possible risk factors related to upstaging of clinical stage T2 organ-confined (OC) to non-OC (nOC) bladder cancer (BC) following radical cystectomy (RC).

Settings and Design: This was a prospective multicenter study.

Subjects and Methods: This is a multicenter prospective study including 196 Egyptian BC patients undergoing RC from January 2017 to February 2019 at Cairo University, Fayoum University, and Menoufia University. Only patients with muscle invasive BC (T2) were included in the study. Patients' characteristics, preoperative clinical data (including Hydronephrosis), cystoscopy data, and biopsy pathological data were recorded. Preoperative clinical staging is compared to postoperative pathological staging, to determine upstaged cases. The occurrence of upstaging in correspondence to each preoperative factor is recorded and statistically analyzed.

Results: Among 196 BC patients of our study, upstaging from OC T2 to nOC occurred in 88 (44.9%) patients. Statistical analysis showed that the factors related to upstaging are older age ($P \leq 0.001$), large tumor size ($P = 0.048$), lymphovascular invasion (LVI) ($P \leq 0.001$), and multifocal tumor ($P \leq 0.001$). On the other hand, the following factors were not related to upstaging: gender ($P = 0.159$), smoking ($P = 0.286$), preoperative hydronephrosis ($P = 0.242$), and presence of carcinoma in situ ($P = 0.349$).

Conclusions: The difference between clinical and pathological staging of BC patients following RC is a frequent problem with no clear guidelines to overcome it. Several factors including age of the patient, large tumor size, LVI, and multifocal tumor are predictors of upstaging in OC BC. A good concern must be taken in these patients to achieve an optimum treatment plan for them.

Keywords: Bladder cancer, nonorgan confined, Organ confined, Radical cystectomy, upstaging

INTRODUCTION

The ninth most commonly diagnosed cancer worldwide is urinary bladder cancer (BC) with an estimated incidence of 430,000 patients in 2012 alone.¹

Transitional cell carcinoma (TCC) is nowadays known to be the most prevalent replacement histopathology of squamous cell carcinoma (SCC). This is may be attributed...
El-Adawy, et al.: Factors related to upstaging of T2 organ-confined bladder cancer

Urology Annals | Volume 14 | Issue 3 | July-September 2022

233

Only patients with OC BC (T2) were included. All 196 consecutive patients suffering from urothelial BC are undergoing RC and lymphadenectomy.

Excluded from this study were patients with nonmuscle invasive BC who were candidates for RC and patients with nOC BC diagnosed by imaging.

Full history with detailed medical history, laboratory investigations in the form of complete blood count, renal function tests, and liver function tests, and radiological investigations in the form of abdominal and pelvic CT with intravenous contrast and chest radiography (in patients with elevated renal functions, MRI of the abdomen and pelvis was done instead of CT) were done for every patient included in the study.

The following clinical and pathological data were analyzed: age, gender, initial BC presentation (date, grade, and stage), intravesical therapies, date of surgery, extent of lymphadenectomy, pre-RC clinical stage, concomitant carcinoma in situ (CIS), and post-RC pathology. Tumor grade was reported as in the 2004 classifications of the International Society of Urologic Pathology (ISUP) and the 2002 Tumor, Nodes, and Metastases (TNM) classification was used to record the stage. The study included only urothelial cancers (UCs).

During TURBT, bimanual examination was performed before resection under general anesthesia. Both specimens of TURBT and RC have been examined by genitourinary pathologists. When the TUR was performed at an outside institution, either TURBT slides were reviewed or rebiopsy was performed at the study institutions.

RC included removal of the bladder, seminal vesicles, and the prostate in males, while the uterus, ovaries, and anterior vaginal wall were included in females.

Extended pelvic lymph node dissection was performed in all patients, the cranial boundary of dissection was the crossing of ureters across the common iliac vessels.

For upstaging, two definitions were used: (1) any increase in T- and/or N-stage, i.e., clinical stages were compared with that following cystectomy, i.e., pathological stage and (2) upstaging from OC to nOC tumor (any cT ≤2, cN0 tumor being upstaged to pT ≥3 or pathologically confirmed node-positive disease).

The data were coded and entered using the Statistical Package for the Social SciencesStatistical Package for
the Social Sciences version 23 (IBM corp., Armonk, NY, USA). Data were compiled using mean, standard deviation, minimum, and maximum in quantitative data and using frequency (count) and relative frequency (percentage) for categorical data.

Correlations were done using Spearman correlation coefficient between quantitative variables. \( P < 0.05 \) was considered statistically significant.

This study was approved by the local ethical committee.

RESULTS

One hundred ninety-six patients with OC BC were included in this study.

The mean age of the studied population is 58.16 ± 7.83. Patients’ demographics are listed in Table 1.

The criteria of the bladder masses diagnosed are listed in Table 2.

Different factors related to upstaging of the bladder masses. Among 196 patients, upstaging from OC T2 to non-OC occurred in 88 (44.9%) patients. Statistical analysis showed that the following factors are related to upstaging: older age \( (P < 0.001) \), larger tumor size \( (P = 0.048) \), multifocal tumor \( (P < 0.001) \), and lymphovascular invasion (LVI) \( (P < 0.001) \).

On the other hand, the following factors were not related to upstaging: gender \( (P = 0.159) \), smoking history \( (P = 0.286) \), preoperative hydronephrosis \( (P = 0.242) \), and presence of CIS \( (P = 0.349) \).

Comparison between preoperative factors in relation to the occurrence of postoperative pathological upstaging is illustrated in Table 3.

DISCUSSION

Physical examination, transurethral resection pathology, and imaging are the mainstay of clinical staging that predict patient outcome and the treatment plan, but the ability to predict pathological stage from clinical stage in BC remains unfortunately limited.\[11\]

In this study, we tried to evaluate different factors that affect upstaging from OC T2 to nOC T2 BC where we found that older age, larger tumor size, multifocal tumor, and LVI are related to upstaging of the disease, while gender, smoking history, preoperative hydronephrosis, and presence of CIS are not related to upstaging of the disease.

Several studies approached the upstaging of pathological examination of BC. In 2012, Turker et al. stated that upstaging was found in tumors with LVI was in agreement with our study, but in contrast, they found that female gender was associated with increased upstaging.\[11\]

In 2013, Mitra et al. agreed with our study where they stated that age, LVI, and tumor growth count were significantly associated with upstaging. In contrary, they found that the presence of hydronephrosis was significantly associated with upstaging.\[12\]

In our study, we studied only the TCC variant of BC without studying other histologic variants, while other studies\[11,13\] identified the role of histological variants in upstaging of the disease and this is attributed to the paradigm shift in histological variants in Egypt from SCC to TCC which is the most common pathology found in pathological specimens.\[2\]

Further studies are needed to study the role of combined treatment (neoadjuvant chemotherapy and RC) in cases with the presence of any factor that may increase the rate of upstaging from OC to nOC disease.

Financial support and sponsorship

Nil.
El-Adawy, et al.: Factors related to upstaging of T2 organ-confined bladder cancer

Conflicts of interest

There are no conflicts of interest.

REFERENCES

1. Antoni S, Ferlay J, Soerjomataram I, Znaor A, Jemal A, Bray F. Bladder cancer incidence and mortality: A global overview and recent trends. Eur Urol 2017;71:96-108.

2. Felix AS, Soliman AS, Khaled H, Zaghloul MS, Banerjee M, El-Baradie M, et al. The changing patterns of bladder cancer in Egypt over the past 26 years. Cancer Causes Control 2008;19:421-9.

3. Bostrom P, Rhiijn B, Fleshner N, Finelli A, Jewett M, Thoms J, et al. Staging and staging errors in bladder cancer. Eur Urol Suppl 2010;9:7.

4. Shariat SF, Palapattu GS, Karakiewicz PJ, Rogers CG, Vazina A, Bastian PJ, et al. Discrepancy between clinical and pathologic stage: Impact on prognosis after radical cystectomy. Eur Urol 2007;51:137-51.

5. Herr HW, Donat Z, Donat SM, Bajorin DF. Defining optimal therapy for muscle invasive bladder cancer. J Urol 2007;177:437-43.

6. Dalbagni G, Genega E, Hashibe M, Zhang ZF, Russo P, Herr H, et al. Cystectomy for bladder cancer: A contemporary series. J Urol 2001;165:1111-6.

7. Madersbacher S, Hochreiter W, Burkhard F, Thalmann GN, Danuser H, Markwalder R, et al. Radical cystectomy for bladder cancer today – A homogeneous series without neoadjuvant therapy. J Clin Oncol 2003;21:690-6.

8. Grossman HB, Natale RB, Tangen CM, Speights VO, Vogelzang NJ, Trump DL, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 2003;349:859-66.

9. Clark PE. Neoadjuvant versus adjuvant chemotherapy for muscle-invasive bladder cancer. Expert Rev Anticancer Ther 2009;9:821-30.

10. Sonpavde G, Sternberg CN. Neoadjuvant systemic therapy for urological malignancies. BJU Int 2010;106:6-22.

11. Turker P, Bostrom PJ, Wroclawski ML, Rhiijn BV, Kortekangas H, Kuk C, et al. Upstaging of urothelial cancer at the time of surgical treatment in the National cancer data base. Urol Oncol 2017;35:34.e1-34.e8.